Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial

JACC: Heart Failure

Volumn 6, Issue 1, 2018, Pages 8-17

  McMurray, John J V ^a   Ponikowski, Piotr ^b   Bolli, Geremia B ^c   Lukashevich, Valentina ^d   Kozlovski, Plamen ^d   Kothny, Wolfgang ^d   Lewsey, James D ^e   Krum, Henry ^f  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY OF PERUGIA   (Italy)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f MONASH UNIVERSITY   (Australia)

Author keywords

diabetes; heart failure

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA; VILDAGLIPTIN; ANTIDIABETIC AGENT;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIOPULMONARY INSUFFICIENCY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG FATALITY; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FUNCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFECTION; INTESTINE OBSTRUCTION; JAUNDICE; LEFT VENTRICULAR INTERNAL DIASTOLIC DIMENSION; LEFT VENTRICULAR INTERNAL SYSTOLIC DIMENSION; LEFT VENTRICULAR MASS INDEX; LEFT VENTRICULAR POSTERIOR WALL THICKNESS; LEFT VENTRICULAR SEPTAL WALL THICKNESS; LEFT VENTRICULAR STROKE VOLUME; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUDDEN CARDIAC DEATH; ADOLESCENT; CLINICAL TRIAL; COMPLICATION; DIAGNOSTIC IMAGING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; SYSTOLE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART VENTRICLES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STROKE VOLUME; SYSTOLE; VENTRICULAR FUNCTION, LEFT; VILDAGLIPTIN; YOUNG ADULT;

EID: 85030853716     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2017.08.004     Document Type: Article

References (30)

1. MacDonald, M.R., Petrie, M.C., Hawkins, et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 29 (2008), 1224–1240.
2. MacDonald, M.R., Petrie, M.C., Varyani, F., et al., for the CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29 (2008), 1377–1385.
3. Dauriz, M., Targher, G., Laroche, C., et al., for the ESC-HFA Heart Failure Long-Term Registry. Association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA Heart Failure Long-Term registry. Diabetes Care 40 (2017), 671–678.
4. Suskin, N., McKelvie, R.S., Burns, R.J., et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 21 (2000), 1368–1375.
5. McMurray, J.J., Gerstein, H.C., Holman, R.R., Pfeffer, M.A., Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2 (2014), 843–851.
6. Crowley, M.J., Diamantidis, C.J., McDuffie, J.R., et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med 166 (2017), 191–200.
7. Fitchett, D.H., Udell, J.A., Inzucchi, S.E., Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur J Heart Fail 19 (2017), 43–53.
8. Komajda, M., McMurray, J.J., Beck-Nielsen, H., et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 31 (2010), 824–831.
9. Hernandez, A.V., Usmani, A., Rajamanickam, A., et al. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 11 (2011), 115–128.
10. Giles, T.D., Elkayam, U., Bhattacharya, M., et al. Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. Congest Heart Fail 16 (2010), 111–117.
11. Dargie, H.J., Hildebrandt, P.R., Riegger, G.A., et al. A randomized, placebo–controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol 49 (2007), 1696–1704.
12. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al., for the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
13. White, W.B., Cannon, C.P., Heller, S.R., et al., for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
14. Green, J.B., Bethel, M.A., Armstrong, P.W., et al., for the TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
15. McGuire, D.K., Van de Werf, F., Armstrong, P.W., et al., for theTrial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol 1 (2016), 126–135.
16. Scirica, B.M., Braunwald, E., Raz, I., et al., for the SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation, 132, 2015, e198.
17. Zannad, F., Cannon, C.P., Cushman, W.C., et al., for the EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385 (2015), 2067–2076.
18. He, Y.L., Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet 51 (2012), 147–162.
19. Cai, L., Cai, Y., Lu, Z.J., et al. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther 37 (2012), 386–398.
20. Schiller, N.B., Acquatella, H., Ports, T.A., et al. Left ventricular volume from paired biplane two-dimensional echocardiography. Circulation 60 (1979), 547–555.
21. Konstam, M.A., Udelson, J.E., Anand, I.S., Cohn, J.N., Ventricular remodeling in heart failure: a credible surrogate endpoint. J Card Fail 9 (2003), 350–353.
22. Cohn, J.N., Ferrari, R., Sharpe, N., Cardiac remodeling: concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol 35 (2000), 569–582.
23. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. for the LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
24. Pfeffer, M.A., Claggett, B., Diaz, R., et al., for the ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
25. Marso, S.P., Bain, S.C., Consoli, A., et al., for the SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
26. Jorsal, A., Kistorp, C., Holmager, P., et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE): a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19 (2017), 69–77.
27. Margulies, K.B., Hernandez, A.F., Redfield, M.M., et al., for the NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316 (2016), 500–508.
28. Inthachai, T., Lekawanvijit, S., Kumfu, S., et al. Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction. Exp Physiol 100 (2015), 667–679.
29. Connelly, K.A., Zhang, Y., Advani, A., et al. DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes. Cardiovasc Ther 31 (2013), 259–267.
30. Yin, M., Silljé H.H., Meissner, M., van Gilst, W.H., de Boer, R.A., Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol, 10, 2011, 85.